-- 根據彭博社週一的分析顯示,由於伊朗和美國的雙重封鎖,霍爾木茲海峽的大部分航運活動已經停滯,只有少數與伊朗有關的船隻仍在航行,而此時油價已超過每桶100美元。 分析指出,伊朗和美國的封鎖已經關閉了霍爾木茲海峽,使這條重要的全球能源通道基本上處於停滯狀態。 分析顯示,由於上週局勢升級後,大多數業者都避開了這條航線,因此只有少數船隻(主要與伊朗有關)仍在通過。 分析稱,上周伊朗砲艇向船隻開火,而美軍扣押了兩艘油輪,這大大增加了風險,並減少了通過該海峽的交通量。 彭博社彙編的船舶追蹤數據顯示,週一上午,三艘與伊朗有關的船隻經霍爾木茲海峽駛出波斯灣,同時沒有船隻進入。 分析報告指出,週一,兩艘與德黑蘭有關的散裝船和一艘液化石油氣運輸船駛離波斯灣,延長了航運活動受限的時期。 報告也指出,週日僅有少數船隻離港,包括一艘與伊朗有關的油輪、一艘散裝貨船和兩艘區域貨船,而一艘與中國有關聯的油輪則駛入波斯灣。 報導稱,幾艘與伊朗有關聯的船隻在駛離波斯灣後仍停留在阿曼灣附近,目前尚不清楚它們是停留進行區域性停靠,還是因美國海軍封鎖而延誤。 繼續航行的船隻使用了一條位於拉拉克島和格甚姆島附近的狹窄北部通道,這條路線已獲得伊朗當局批准,允許有限通行。 分析報告指出,美國的封鎖導致船隻關閉追蹤訊號,降低了能見度,使得實際交通流量的測量更加困難。 報告還指出,由於追蹤數據有限,當船隻在危險區域外重新出現時,可能會出現更高的船舶數量報告,這表明即時監控存在漏洞。 分析稱,即使在最近的限制措施之前,與伊朗有關的船隻也經常在霍爾木茲附近停止跟踪,並在距離哈爾格島約 13 天的馬六甲海峽附近重新激活信號。
Related Articles
Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set
Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.
Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.